Navigation Links
Cancer trial information leaflets 'not fit for purpose'- new study
Date:3/26/2012

Patient information leaflets for cancer trials are not up to the job, reveals a new study from the University of Leicester.

Research published in the international journal Sociology of Health and Illness reveals that patients find the leaflets far too long and incomprehensible, and even intimidating.

"These information sheets are poorly aligned with patients' information needs and how they really make decisions about whether to join a cancer trial," said author Professor Mary Dixon-Woods, Professor of Medical Sociology at the University of Leicester Department of Health Sciences.

"Some patients did find them very useful, but many others paid them little attention. They preferred to rely on discussions they had with their doctor to make up their minds."

The study aimed to unravel the mystery of why cancer trial information sheets are so hard to get right. Conducted as a collaboration between the Departments of Health Sciences and Cancer Studies at the University of Leicester, it traced what happened in 13 cancer trials. It looked at information sheets from the time they were prepared by the researchers leading the trials, through being reviewed and approved by research ethics committees. The study interviewed 26 patients who were approached to take part in trials and were given the information sheets.

"We found that research ethics committee examine information sheets very carefully. They are genuinely keen to make sure that patients are not misled in any way and that the information sheets are easy to read. They very often ask researchers to make changes to make sure they are suitable," said author Dr Natalie Armstrong, Lecturer in Social Science Applied to Health.

"The problem is that information sheets are trying to do too many things. They end up having many of the features of a legal contract. Patients often find them far too long and incomprehensible, and even intimidating. In fact, many patients believed that the information sheets weren't really produced for their benefit at all, but were more about researchers and institutions 'covering their backs'".

One patient in the study said: "There was a lot of jargon that didn't really necessarily need to be in there. I think that there was a lot of information that sort of baffled you."

There are things that could be done to improve cancer trial information sheets, the study concludes.

"Rather than using standardised templates, it might be better to have a list of principles that could be used when writing information sheets. It could also be valuable to involve patients themselves in helping to write and review them," commented Dr Armstrong. "But we also have to accept that patients may continue to make their decisions about taking part in trials based on trust in their doctor, no matter how well written the information sheets are. We need to find ways to support doctors when recruiting to trials."


'/>"/>
Contact: Professor Mary Dixon-Woods
md11@le.ac.uk
44-011-622-97262
University of Leicester
Source:Eurekalert  

Related medicine news :

1. Cancer treatment system sculpts radiation beam to match shape of a tumor
2. Few young women with cancer take steps to preserve fertility during treatments
3. Non-drug treatments help alleviate symptoms of treatment-induced menopause in breast cancer patients
4. Stress management for breast cancer patients may affect disease course
5. Nemours researchers uncover new evidence of cancer-causing agent present in gaseous phase of cigarette smoke
6. Obscurins in breast tissue may help physicians predict and detect breast cancer
7. Study: Low bone density medications may have protective effect on endometrial cancer
8. Parents of children with cancer distrust and fear online sources of health information, study shows
9. ASCO honors Ching-Hon Pui, M.D., for work advancing childhood cancer research and treatment
10. Have I got cancer or havent I? Medical staff confuse women with ductal carcinoma in situ
11. Dense breasts can nearly double the risk of breast cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer trial information leaflets 'not fit for purpose'- new study
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: